APUS · Apimeds Pharmaceuticals US, Inc.
$5.65
+5.00 (+764.84%)
At close · Jul 24
Going-concern doubt
— flagged May 26, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not contain any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed May 26, 2026
Market Cap
$85.27M
Shares
15.09M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$6M
-331.7%
FY2025
Diluted EPS
-$0.55
-205.6%
FY2025
Operating Cash Flow
-$8.93M
-1116.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $1.63M | — | $98.54K | |
| $21.2M | $10.28M | $1.28M | $648.89K | |
| $23.73M | $11.91M | $1.28M | — | |
| -$23.73M | -$11.91M | -$1.28M | -$747.44K | |
| $1.1M | $283.01K | $117.72K | $38.07K | |
| $107.6K | $107.6K | $2824 | $7811 | |
| -$16.92M | $5.91M | -$114.9K | -$30.26K | |
| -$40.66M | -$6M | -$1.39M | -$777.69K | |
| USD/shares | — | -$0.55 | -$0.18 | -$1.70 |
| USD/shares | — | -$0.55 | -$0.18 | -$1.70 |
| shares | — | 10.88M | 7.9M | 459.83K |
| shares | — | 10.88M | 7.9M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.97×
EV/EBIT
—
P/E (TTM)
—
Peer median 12.14×
Peer medians compare against the 43 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).